| Literature DB >> 32095080 |
Mona Wassef1, Ahmed Mukhtar2, Ahmed Nabil3, Moushira Ezzelarab1, Doaa Ghaith1.
Abstract
INTRODUCTION: Surgical site infections (SSIs) are one of the most frequently reported hospital acquired infections associated with significant spread of antibiotic resistance.Entities:
Keywords: ICU; MDR- Acinetobacter; OXA 48; colonization
Year: 2020 PMID: 32095080 PMCID: PMC6995287 DOI: 10.2147/IDR.S236814
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Figure 1Chromogenic media (ChromID OXA-48) for detection of OXA-48-type carbapenemase-producing Enterobacteriaceae.
Figure 2CHROMagar Acinetobacter for detection of MDR A. baumannii.
Operative Data for All Patients Who Had Surgery at the SICU During the Phase I and Phase III. Data are Presented as Frequencies (Percent)
| Phase I (Total 177) | Phase III (Total 93) | P-value | |||
|---|---|---|---|---|---|
| Count | % | Count | % | ||
| Type of Operation | |||||
| Head and neck | 4 | 2.2% | 1 | 1.1% | |
| Abdominal | 103 | 58.1% | 51 | 54.8% | |
| Vascular | 27 | 15.3% | 18 | 19.4% | |
| Neurosurgery | 17 | 9.6% | 11 | 11.8% | |
| Orthopedic | 12 | 6.8% | 8 | 8.6% | |
| Urology | 5 | 2.8% | 3 | 2.1% | |
| Cardiothoracic | 5 | 2.8% | 0 | 0.0% | |
| Plastic | 2 | 1.1% | 1 | 1.1% | |
| Obstetrics and Gynecology | 1 | 0.6% | 0 | 0.0% | |
| Ophthalmic | 1 | 0.6% | 0 | 0.0% | |
| Abdominal and Vascular | 0 | 0.0% | 1 | 1.1% | |
| Class of wound | |||||
| Clean | 66 | 37.5% | 31 | 33.7% | 0.063 |
| Clean contaminated | 76 | 43.2% | 36 | 39.1% | |
| Contaminated | 24 | 13.6% | 23 | 25.0% | |
| Dirty | 10 | 5.7% | 2 | 2.2% | |
| Duration of surgery | |||||
| One hour | 52 | 29.5% | 21 | 22.8% | 0.175 |
| Two hours | 57 | 32.4% | 26 | 28.3% | |
| Three hours | 61 | 34.7% | 37 | 40.2% | |
| More than three hours | 6 | 3.4% | 8 | 8.7% | |
| Antibiotic prophylaxis | 96 | 54.2% | 86 | 92%* | <0.001 |
| Devices | |||||
| Urinary catheter | 107 | 60.5% | 62 | 66.7% | 0.316 |
| Ventilator | 105 | 59.3% | 37 | 39.8%* | 0.001 |
| Drain | 103 | 58.1% | 51 | 54.8% | 0.597 |
Note: *Denotes significant difference between both groups.
Details of Surgical Site Infection in Phase I and III
| Phase I (Total 49/177) | Phase III (Total 14/93) | P-value | |||
|---|---|---|---|---|---|
| Count | % | Count | % | ||
| SSI Rate | 49 | 27.6% | 14 | 15.0% | <0.001 |
| Type of SSI | |||||
| Deep | 22 | 45.8% | 7 | 53.8% | 0.837 |
| Deep with organ | 25 | 52.1% | 6 | 46% | |
| Superficial | 1 | 2.1% | 0 | 0.0% | |
| Causative organism | |||||
| | 17 | 34.7% | 4 | 30.8% | 0.108 |
| Mixed Colonizers | 11 | 22.4% | 0 | 0.0% | |
| | 7 | 14.3% | 5 | 38.5% | |
| No growth | 6 | 12.2% | 1 | 7.7% | |
| Methicillin-resistant Staph aureus (MRSA) | 3 | 6.1% | 0 | 0.0% | |
| | 2 | 4.1% | 2 | 15.4% | |
| | 1 | 2.0% | 0 | 0.0% | |
| | 1 | 2.0% | 0 | 0.0% | |
| | 1 | 2.0% | 0 | 0.0% | |
| | 0 | 0.0% | 1 | 7.7% | |
| Pattern of resistance | |||||
| Extended spectrum B lactamase (ESBL) | 3 | 6.1% | 1 | 7.1% | 0.119 |
| AmpC | 6 | 12.2% | 1 | 7.1%* | 0.007 |
| AmpC and ESBL | 1 | 2.0% | 0 | 0% | 0.345 |
Note: *Denotes significant difference between both groups.
The Table Shows the Decolonization Rate in the Phase III
| Screening | First Sample (Total 77) | Second Sample (Total 68) | P-value | |||
|---|---|---|---|---|---|---|
| Count | % | Count | % | |||
| Acinetobacter MDR screening (nasal and axillary) | Yes | 33 | 42.8% | 11 | 16.1% | 0.005 |
| First sample (Total 71) | Second sample (Total 62) | P-value | ||||
| Acinetobacter MDR screening (anal) | Yes | 45 | 63.3% | 21 | 33.87% | 0.007 |
| Screening | First sample (Total 80) | Second sample (Total 54) | P-value | |||
| OXA 48 MDR screening | 26 | 32.5% | 6 | 11% | 0.004 | |
| No growth | 40 | 50% | 42 | 77.7% | 0.001 | |
| 7 | 8.7% | 6 | 11% | 0.652 | ||
| Both | 7 | 8.7% | 0 | 0% | 0.001 | |
Antibiotics Used in the Treatment of Patients in Phases I and III
| Phase I Total (177) | Phase III Total (93) | P-value | |||
|---|---|---|---|---|---|
| Count | % | Count | % | ||
| Imipenem | 108 | 61% | 36 | 38.7%* | 0.011 |
| Vancomycin | 90 | 51.0% | 6 | 6.5%* | < 0.001 |
| Cefepime | 7 | 4.0% | 32 | 34.4%* | < 0.001 |
| Cefoperazone/sulbactam | 4 | 2.0% | 0 | 0.0% | 0.345 |
| Clindamycin | 14 | 8.0% | 6 | 6.5% | 0.737 |
| Piperacillin/tazobactam | 7 | 4.0% | 5 | 5.4% | 1 |
| Metronidazole | 0 | 0.0% | 11 | 11.8%* | 0.016 |
| Tigecycline | 0 | 0.0% | 2 | 2.2% | 0.545 |
| Meropenem | 7 | 4.0% | 14 | 15.1%* | 0.049 |
| Fluconazole | 4 | 2.0% | 6 | 6.5% | 0.422 |
| Teicoplanin | 0 | 0.0% | 4 | 4.3% | 0.298 |
| Ceftriaxone | 7 | 4.0% | 1 | 1.1% | 0.274 |
Note: *Denotes significant difference between both groups.
Figure 3Compliance with bundle components (total 93 patients).